Moderna Says Vaccine Is Effective In Vitro Against New COVID-19 Variants

Kimberly Redmond  |

Image source: Moderna Therapeutics

Moderna is tweaking its COVID-19 vaccine to make it more effective against emerging strains of the virus, the company announced Monday.

In recent weeks, new variants of the virus have popped up in the United Kingdom and South Africa, along with worries that vaccines would be less protective against the strains.

Although lab studies have shown the current vaccine – which was authorized by the US FDA in December 2020 – appears to provide protection against the two highly transmissible strains, results indicate that the two-dose vaccination may be less effective against the South African variant, according to the Massachusetts-based pharmaceutical company.

In response, Moderna chief executive Stéphane Bancel said it is accelerating work on two booster shots – one aimed at the South African strain and another to fight new mutations.

Upgrades to the two-dose regime, Bancel noted, are being developed “out of an abundance of caution.”

“As we seek to defeat the COVID-19 virus, which has created a worldwide pandemic, we believe it is imperative to be proactive as the virus evolves,” he said.

The company’s announcement comes a few days after White House chief medical advisor Dr. Anthony Fauci said the Biden administration is “paying very close attention” to variants, especially since new data showed the vaccines currently on the market may not be as effective in guarding against new strains.

The news also follows a warning earlier this month from the Centers for Disease Control and Prevention that the UK variant could become the dominant strain in the US by March.


Source: Equities News




Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

Trending Articles

Remote and Hybrid Work Is Boosting Commercial Air Travel
Silicon Valley ‘Open Secret’ Means Buy This World-Class Tech Stock
Natural Gas and Energy: Expect Dramatic Price Swings Near-Term
The Boulevard of Broken Dreams
Prepare For the December Oil Shock
Next Phase of Pharma Growth: Generics
Three Slam-Dunk Opportunities as the Inflation Nightmare Weakens
T-Mobile Was First to 5G Data, But Forgot Voice: Jeff Kagan

Market Movers

Sponsored Financial Content